JP2015508284A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508284A5
JP2015508284A5 JP2014548019A JP2014548019A JP2015508284A5 JP 2015508284 A5 JP2015508284 A5 JP 2015508284A5 JP 2014548019 A JP2014548019 A JP 2014548019A JP 2014548019 A JP2014548019 A JP 2014548019A JP 2015508284 A5 JP2015508284 A5 JP 2015508284A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
nucleic acid
homodimeric protein
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014548019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508284A (ja
JP6258864B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/076404 external-priority patent/WO2013092875A1/en
Publication of JP2015508284A publication Critical patent/JP2015508284A/ja
Publication of JP2015508284A5 publication Critical patent/JP2015508284A5/ja
Application granted granted Critical
Publication of JP6258864B2 publication Critical patent/JP6258864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014548019A 2011-12-21 2012-12-20 Hpvに対するワクチン Active JP6258864B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578542P 2011-12-21 2011-12-21
US61/578,542 2011-12-21
PCT/EP2012/076404 WO2013092875A1 (en) 2011-12-21 2012-12-20 Vaccines against hpv

Publications (3)

Publication Number Publication Date
JP2015508284A JP2015508284A (ja) 2015-03-19
JP2015508284A5 true JP2015508284A5 (enExample) 2016-02-18
JP6258864B2 JP6258864B2 (ja) 2018-01-10

Family

ID=47471832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548019A Active JP6258864B2 (ja) 2011-12-21 2012-12-20 Hpvに対するワクチン

Country Status (17)

Country Link
US (1) US9901635B2 (enExample)
EP (2) EP2793937B1 (enExample)
JP (1) JP6258864B2 (enExample)
KR (1) KR102057265B1 (enExample)
CN (1) CN104039833B (enExample)
AU (1) AU2012356969B2 (enExample)
BR (1) BR112014015016B1 (enExample)
CA (1) CA2858963C (enExample)
DK (1) DK2793937T3 (enExample)
ES (1) ES2730718T3 (enExample)
HU (1) HUE043361T2 (enExample)
IL (1) IL233217B (enExample)
PT (1) PT2793937T (enExample)
RU (1) RU2644201C2 (enExample)
TR (1) TR201908199T4 (enExample)
WO (1) WO2013092875A1 (enExample)
ZA (1) ZA201404516B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970466A1 (en) * 2013-03-15 2016-01-20 Vaccibody AS Targeting vaccines for veterinary use
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
AU2015302930C1 (en) 2014-08-15 2023-06-01 Genexine, Inc. Methods of treating cervical cancer
BR112018003019A2 (pt) * 2015-08-20 2018-09-25 Janssen Vaccines & Prevention Bv vacinas terapêuticas contra hpv18
KR102833333B1 (ko) * 2016-01-08 2025-07-11 니코데 테라퓨틱스 에이에스에이 치료적 항암 네오에피토프 백신
JP2020533338A (ja) 2017-09-07 2020-11-19 ユニバーシティ オブ オスロUniversity of Oslo ワクチン分子
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
JP2023522588A (ja) 2020-04-09 2023-05-31 ナイコード セラピューティクス アルメン アクスイェ セルスカプ 個別化された治療用抗がんワクチン
US11883479B2 (en) 2020-04-24 2024-01-30 Genexine, Inc. Method for treating cervical cancer
KR20230005962A (ko) 2020-05-01 2023-01-10 니코데 테라퓨틱스 에이에스에이 베타코로나바이러스 예방 및 치료요법
CA3212592A1 (en) 2021-03-26 2022-09-29 Agnete Fredriksen Therapeutic combination for treating cancer
US20250339509A1 (en) 2021-05-03 2025-11-06 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
CA3216720A1 (en) 2021-05-10 2022-11-17 Agnete Brunsvik Fredriksen Co-expression of constructs and immunostimulatory compounds
JP2024518463A (ja) 2021-05-10 2024-05-01 ナイコード セラピューティクス アルメン アクスイェ セルスカプ 構築物及び免疫阻害化合物の共発現
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2022238395A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
KR20240007235A (ko) 2021-05-10 2024-01-16 니코데 테라퓨틱스 에이에스에이 관용-유도 컨스트럭트 및 조성물 및 면역 장애의 치료를 위한 그들의 용도
JP2024540322A (ja) 2021-11-03 2024-10-31 ナイコード セラピューティクス アルメン アクスイェ セルスカプ SARS-CoV-2によって引き起こされる疾患の予防及び処置に使用するための免疫原性構築物及びワクチン
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
US7223408B2 (en) * 2002-10-03 2007-05-29 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
CA2517054C (en) * 2003-02-25 2016-05-10 Medinnova As Use of nucleic acids encoding antibody-like molecules for use in medical treatment
PT1576967E (pt) * 2004-03-18 2007-12-03 Pasteur Institut Proteína recombinante que transporta epitopos do virús do papilloma humano inseridos numa proteína adenilato ciclase, ou no seu fragmento, e seus usos terapêuticos
WO2006081323A2 (en) 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
KR20130087517A (ko) * 2010-06-25 2013-08-06 백시바디 에이에스 동종이합체 단백질 구조물

Similar Documents

Publication Publication Date Title
RU2014129788A (ru) Вакцины против hpv
CN108434450B (zh) 基于铁蛋白纳米颗粒的疫苗及其制备方法
JP2013532971A5 (enExample)
Liu et al. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture
JP2012095652A5 (enExample)
JP6974358B2 (ja) Hpv l2ペプチドの免疫原性の改善
RU2013103335A (ru) Конструкции гомодимерных белков
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
WO2008098484A1 (en) Recombinant l1 proteins of human papilloma virus and uses thereof
JP2019506175A5 (enExample)
JP2010166921A5 (enExample)
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
JP2014534202A5 (enExample)
CN104710515B (zh) 人乳头瘤病毒l1蛋白突变体及其制备方法
JP2015501840A5 (enExample)
AR045804A1 (es) Expresion optimizada de l1 del vph45 en levaduras
JP2012515557A5 (enExample)
JP2014519817A5 (enExample)
JP2026500600A (ja) Hpv感染関連疾患を予防又は治療するためのポリヌクレオチド分子
JP2021516991A5 (enExample)
CN105296521A (zh) 表达可溶性人乳头瘤病毒16亚型l1蛋白的重组质粒及其表达方法
JP2014530224A (ja) ノロウイルス感染に対するワクチンとしての自己集合ペプチドナノパーティクル
JP2013531991A5 (enExample)
JP2019502404A5 (enExample)
JP2010538619A5 (enExample)